Myopia Control With a Innovative Spectacle Lens

Essilor

Status

Completed

Conditions

Myopia

Treatments

Device: Single vision spectacle lens

Device: innovative myopia control spectacle lens

Study type

Interventional

Funder types

Industry

Identifiers

WS10246

Details and patient eligibility

About

The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.

Enrollment

159 patients

Sex

All

Ages

6 to 12 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Equal to or greater than 6 years and not older than 12 years at time of informed consent and assent.
Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.50 D in each eye.
Astigmatism, if present, of not more than 1.50 D.
Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
Agree to wear spectacles for ≥10 hours/day at least 6 days/week.
Willingness and ability to participate in trial for 3 years and attend scheduled visits.

Exclusion criteria

History of myopia control intervention (e.g., atropine, orthokeratology, multifocal contact lenses, etc.)
Strabismus by cover test at near or distance wearing correction.
Amblyopia
Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.).
Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
Current or anticipated use of growth hormones.
Participation in any clinical study within 30 days of the Baseline visit.